US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Altamira Therapeutics Ltd.

0.0750

-0.0250-25.00%

Volume:4.68K

Turnover:420.63

Market Cap:428.66K

PE:-0.06

High:0.1000

Open:0.1000

Low:0.0750

Close:0.1000

52wk High:0.2000

52wk Low:0.0501

Shares:5.72M

Float Shares:4.64M

Volume Ratio:1.38

T/O Rate:0.10%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.3114

EPS(LYR):-2.9862

ROE:-108.79%

ROA:-45.75%

PB:0.11

PE(LYR):-0.03

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Altamira Therapeutics Wins China Approval for Bentrio Nasal Spray

Altamira Therapeutics Secures EU MDR Certification for Bentrio Nasal Spray

Altamira Therapeutics Achieves Successful DNA Delivery with Nanoparticle Technology

Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CYTOF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CYTOF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYTOF\",,,,,undefined,":{"symbol":"CYTOF","market":"US","secType":"STK","nameCN":"Altamira Therapeutics Ltd.","latestPrice":0.075,"timestamp":1766178000000,"preClose":0.1,"halted":0,"volume":4684,"delay":15,"floatShares":4642100,"shares":5715500,"eps":-1.311435,"marketStatus":"Market Closed","change":-0.025,"latestTime":"12-19 16:00:00 EST Delay","open":0.1,"high":0.1,"low":0.075,"amount":420.625,"amplitude":0.25,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-1.311435,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766394000000},"marketStatusCode":7,"adr":0,"exchange":"PINK","adjPreClose":0.1,"volumeRatio":1.3823633777352642},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CYTOF\",,,,,undefined,":{"symbol":"CYTOF","floatShares":4642100,"roa":"-45.75%","roe":"-108.79%","lyrEps":-2.986177,"volumeRatio":1.3823633777352642,"shares":5715500,"dividePrice":0,"high":0.1,"amplitude":0.25,"preClose":0.1,"low":0.075,"week52Low":0.0501,"pbRate":"0.11","week52High":0.2,"institutionHeld":0,"latestPrice":0.075,"eps":-1.311435,"divideRate":0,"volume":4684,"delay":15,"ttmEps":-1.311435,"open":0.1,"prevYearClose":0.1105,"prevWeekClose":0.0912,"prevMonthClose":0.065,"prevQuarterClose":0.06,"fiveDayClose":0.0912,"twentyDayClose":0.071,"sixtyDayClose":0.06},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CYTOF\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CYTOF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CYTOF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CYTOF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2592160375","title":"Altamira Therapeutics Wins China Approval for Bentrio Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2592160375","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592160375?lang=en_us&edition=fundamental","pubTime":"2025-12-19 22:00","pubTimestamp":1766152817,"startTime":"0","endTime":"0","summary":"Altamira Therapeutics Ltd. has announced that its associate company, Altamira Medica, has received marketing approval from the National Medical Products Administration  of China for its Bentrio nasal spray for the treatment of allergic rhinitis. This regulatory clearance enables Nuance Pharma, Altamira Medica's licensee and distribution partner, to begin marketing and distributing Bentrio in Mainland China. The approval is significant given that nearly 200 million people in China are estimated to suffer from allergic rhinitis.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altamira Therapeutics Ltd. published the original content used to generate this news brief via ACCESS Newswire  on December 19, 2025, and is solely responsible for t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL5mJHW2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CYTOF"],"gpt_icon":0},{"id":"2584137346","title":"Altamira Therapeutics Secures EU MDR Certification for Bentrio Nasal Spray","url":"https://stock-news.laohu8.com/highlight/detail?id=2584137346","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584137346?lang=en_us&edition=fundamental","pubTime":"2025-11-20 22:00","pubTimestamp":1763647253,"startTime":"0","endTime":"0","summary":"Altamira Therapeutics Ltd. announced that its associate company, Altamira Medica, has obtained certification for its Bentrio nasal spray under the European Union's Medical Device Regulation . This certification confirms Bentrio's conformity with the EU's new, more stringent requirements for medical devices, enabling its commercialization across EU member states and facilitating regulatory approval in other countries. The MDR certification follows significant investment and clinical trials by Medica and marks a key milestone in the international expansion of Bentrio. There is no indication that funding or grant support was provided by organizations other than Altamira or its associate company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251120:nNDL9vVX1m:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CYTOF"],"gpt_icon":0},{"id":"2580221935","title":"Altamira Therapeutics Achieves Successful DNA Delivery with Nanoparticle Technology","url":"https://stock-news.laohu8.com/highlight/detail?id=2580221935","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580221935?lang=en_us&edition=fundamental","pubTime":"2025-11-03 22:00","pubTimestamp":1762178446,"startTime":"0","endTime":"0","summary":"Altamira Therapeutics Ltd. has announced successful results from in vitro experiments demonstrating efficient delivery of DNA molecules using its xPhore nanoparticle technology. The company reported effective transfection of cells and reliable expression of encoded proteins, showcasing the potential of its peptide-based delivery platform for large payloads like plasmid DNA. Altamira will offer this technology to biotech and pharmaceutical partners under the GenePhore label, targeting applications such as DNA vaccines, gene editing, and protein replacement therapies. The announcement did not specify if or when these results will be presented at a scientific conference or publication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altami","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251103:nNDL1kYZC2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CYTOF"],"gpt_icon":0},{"id":"2563014047","title":"Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2563014047","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2563014047?lang=en_us&edition=fundamental","pubTime":"2025-08-29 19:42","pubTimestamp":1756467776,"startTime":"0","endTime":"0","summary":"Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments. Altamira Therapeutics Ltd. has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL6NvttB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CYTOF"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/CYTOF\",params:#limit:6,delay:false,,,undefined,":[]}}